Krystal Biotech (BSP:K1YS34) Total Liabilities: R$629 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:K1YS34 Krystal Biotech Inc BSP:K1YS34
54 GF Score
Price R$44.80
GF Value R$40.31
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech Total Liabilities?

Krystal Biotech BSP:K1YS34 54 Total Liabilities is R$629 Mil as of Mar. 2026. GuruFocus rates BSP:K1YS34 with a GF Score™ of 54/100 and a GF Value™ of R$40.31. The stock has 6 warning signs investors should review.

Krystal Biotech's Total Liabilities for the quarter that ended in Mar. 2026 was R$629 Mil.

Krystal Biotech's quarterly Total Liabilities increased from Sep. 2025 (R$548.20 Mil) to Dec. 2025 (R$623.23 Mil) and increased from Dec. 2025 (R$623.23 Mil) to Mar. 2026 (R$628.80 Mil).

Krystal Biotech's annual Total Liabilities increased from Dec. 2023 (R$194.59 Mil) to Dec. 2024 (R$667.80 Mil) but then declined from Dec. 2024 (R$667.80 Mil) to Dec. 2025 (R$623.23 Mil).

Krystal Biotech Total Liabilities Historical Data

* Premium members only.

The historical data trend for Krystal Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krystal Biotech Total Liabilities Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 185.02 189.98 194.59 667.80 623.23

Krystal Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 516.74 542.09 548.20 623.23 628.80
BSP:K1YS34
54GF Score
Krystal Biotech Inc BSP:K1YS34
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Krystal Biotech's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=561.621+(41.289+20.316
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=623

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=7276.78-6653.553
=623

Krystal Biotech's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=563.761+(38.239+26.797
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=629

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=7305.579-6676.782
=629

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of R$629 Mil mean?
Krystal Biotech (BSP:K1YS34) has a Total Liabilities of R$629 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Krystal Biotech and its competitors.
Is Krystal Biotech's Total Liabilities too high?
Krystal Biotech's current Total Liabilities is R$629 Mil. Overall, Krystal Biotech has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Total Liabilities compare to NUVL and HALO?
Krystal Biotech's Total Liabilities of R$629 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Krystal Biotech and its competitors. Krystal Biotech's current Total Liabilities is R$629 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Krystal Biotech (BSP:K1YS34) has a current Total Liabilities of R$629 Mil. The stock's GF Value™ is R$40.31, compared to a current price of R$44.80 — trading 11.1% above its estimated fair value. The current Total Liabilities is R$629 Mil. Krystal Biotech's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Krystal Biotech (BSP:K1YS34), the current Total Liabilities is R$629 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (BSP:K1YS34) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of R$44.80 is trading 11.1% above its estimated GF Value™ of R$40.31.

Key valuation signals for BSP:K1YS34:

  • Total Liabilities: R$629 Mil
  • GF Value™: R$40.31 vs. price of R$44.80 (11.1% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the BSP:K1YS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
54GF Score

Get the complete analysis for BSP:K1YS34

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$44.80
Price
R$40.31
GF Value